Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]
Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]
Clinical trial number NCT03108482 for "Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial." at ClinicalTrials.gov